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Abstract
Theprogresswhichhasbeenmadeinthetherapyofpatientswithhead
and neck cancer in recent years mainly concern the HPV associated
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HNSCC and the quality of life. The overall survival of patients carrying
1 Klinik für Hals-, Nasen- und
Ohrenheilkunde,
non HPV associated HNSCC during the last thirty years has not experi-
enced any significant improvement and must be referred to as static Medizinische Fakultät
Lübeck, Germany [1], [2]. The problem of the illness remains unchanged in the frequent
and poorly controllable relapse situation. The locoregionally originating
tumours or lymph node metastases show a considerably poorer re-
sponse towards current therapies. Likewise for a number of patients a
formation of distant metastases seems to develop during the course
of the illness. Those distant metastases are also therapeutically rather
difficulttocontrol.ThereforethemortalityofthenonHPVinducedhead
and neck cancer remains unchanged.
The term “stem cell” describes the entity cell, which acts as a reservoir
fornewcellsinordertoreplacedefectiveornecroticcells.Afundament-
al characteristic of stem cells is the constant ability to multiply into dif-
ferent type of cells, which subsequently do not proliferate.
With the insight of new knowledge within the regenerative medicine
and the ability of stem cells of self regenerating proliferation and their
multipotency in the differentiation, the origin of cancer attains a new
distinction. If you look on the tumour as a malignant wound it becomes
obvious, that the regeneration or the composition of additional tissue
depends on the presence and differentiation of stem cells. The wound
healing,whichisaregenerationoftissuedependsnotonlyonstationary
stem cells. In fact stem cells are attracted for “homing” in the defective
areasbydespatchofvariousmessengers,whichthenformandreplace
the vascular tree or other tissue [3], [4].
Next to those stem cells, which functionally help to form tumour tissue,
a small entity of “real cancer stem cells” in solid tumours is expected.
Those occur in tumours and they have typical stem cell characteristics
likeself-regenerationandthepotentialofdifferentiationandarepoten-
tiallyresponsiblefortumourgrowth.Withtheirabilityofself-regeneration
theywouldhavetheabilitytoformacompletetumouroutofeverysingle
cell. That tumour would histologically look like the tumour those cells
initially originated from. Of particular interest regarding those currently
still elusive cancer stem cells is their resistance towards current ther-
apies like radiotherapy or chemotherapy. Those insights now get a
completely new meaning in tumour biology: Does a cancer stem cell
exist, which is able to initiate and keep up tumour growth despite all
possible therapeutic interventions?
This presentation will outline the current views regarding cancer stem
cellsinnonHPVassociatedHNSCCanditwillhighlightproblems,which
are currently researched on. The objective must be to understand the
biology of those cells in a way that make an extended range of thera-
peuticspossible.Atherapy,whichspecificallytargetscancerstemcells,
could improve the chances of recovery.
Keywords: head and neck squamous cell cancer (HNSCC), stem cells,
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Currentlythedegreeofcontributionofstemcellstowards
the regeneration of cancer is widely not understood.
Resulting of my own observations and analysis of literat-
ure it becomes clear, that HNSCC is infiltrated by a large
number of stem cells [5]. For many of those stem cells it
unclear where they originate from. The source could be
either in the bone marrow or in peripheral tissue [6], [7].
UsingtheexampleoftheCD34progenitorcellsdescribed
below the implication of such infiltrating stem cells will
behighlighted,wherebyfarmorecellscarryingstemcells
markers are present in HNSCC [8].
1.1 Infiltrating CD34 progenitor cells in
development and therapy of HNSCC
Over the last years it became obvious that adult stem
cells and their precursor contain a highly therapeutical
potential. Beside their usage within the regenerative
medicinethereareincreasingindicationsforapromising
usage within oncology [9]. A number of studies could
demonstrate that CD34
pos. cells are mobilised from the
bone marrow into the bloodstream by GM-CSF which is
produced by head and neck carcinomas [10], [11]. Fur-
thermore the CD34
pos. cells are chemotacticly attracted
by the head and neck carcinoma by means of VEGF [12].
Thepossiblebiologicalbackgroundismany-faceted;stem
cells can be involved in neoangiogenesis in order to im-
prove the deficient blood supply in the tumour [4], [13].
Furthermore it seems thinkable, that the tumour, based
on the deliberations in terms of a tumour stem cell, pro-
motes the differentiation of the entering CD34
pos. cells in
tumour cells.
Ithasbeendemonstratedthathemopoietic,mesenchymal
and endothelial progenitor cells from the bone marrow
play a central role in the synthesis of the tumour stroma
and in the neoangiogenesis [9], [14]. By means of genet-
ically modified stem cells antitumoural effects in animal
models had been already achieved [15], [16], [17]. In
additiontoittheelucidationandusageoftumourspecific
stem cell recruitment opens the possibility to induce effi-
cient graft-versus-leukaemia effects in the context of al-
logenic stem cell transplantations. The genetic modifica-
tions of those cells could, in the context of autologous
stem cell transplantations, induce antitumoural effects
without damaging the normal tissue. Moreover a broad
clinical basis for a safe clinical application of those cells
exists,becauseabonemarrowtransplantation/stemcell
therapy after myeloablative treatment is, for many years,
an inherent part of therapy protocols. Additionally those
cells are relatively easy to isolate, to multiply and can be
genetically modified transiently or permanently in many
ways. Hence the expansion of knowledge of those cells
within oncology is crucial for the development of new
HNSCC therapies [3], [11], [18], [19], [20], [21], [22],
[23], [24], [25], [26], [27], [28], [29], [30].
In addition more recent studies have shown, those stem
cells develop potent immunosuppressive characteristics
under the influence of the tumour environment. It was
shown, that T cells obtained from a head and neck car-
cinoma are significantly limited in their ability to secrete
IL-2. However, if one removes the CD34
pos. cells from the
cell lysates, a distinctly higher IL-2 secretion manifested.
On the other hand adding additional CD34
pos. cells had
the same effect and lead to a significant suppression of
the IL-2 secretion [31].
Furthermore it was shown, that the response rate of
T cells obtained from a head and neck carcinoma to a IL-
2 stimulus in an autocrine stimulation sense is perman-
ently restricted. While a normal T cell population reacts
toanIL-2stimuluswithahighproliferationrate,solimited
is, on the contrary, the beneficent reaction under the in-
fluence of CD34
pos. cells. The response rate to such a
stimulus is lowered. In the same way, however, the re-
sponse rate to an IL-2 stimulus can be normalised by re-
moving the CD34
pos. cells from the cell lysates [31]. This
immunosuppressiveinfluenceofthosecellsisapparently
moderatedviasecretionofTGF-bandothercytokinesvia
CD34
pos. cells. In further studies the above-mentioned ef-
fects of the CD34
pos. cells have been averted by means
of antibody based blocking of the TGF-F receptors [31],
[32], [33] (Figure 1).
The reflection was deduced from the research results
mentionedabove,whichistobypassnotonlytheimmun-
osuppressive characteristics of the CD34
pos. cells via dir-
ected differentiation, but also to influence via directed
differentiationtheircharacteristicsasadirectedimmune
response against the tumour [34]. In this context those
studies are of great interest, which could demonstrate,
that CD34
pos. cells obtained from patients with head and
neck carcinoma can differentiate to dendritic cells [35],
[36], [37]. In present tests to recruit dendritic cells as an
antitumoural immunotherapeutic, often the number of
the cells to be recruited represents the limiting factor.
Based on the fact, that a peripherally increased level of
CD34
pos. cells could be verified on patients with head and
neck cancer, this could represent an elegant and prom-
ising new approach in terms of an antitumoural immuno-
therapy [38], [39], [40].
2. Cancer stem cells
Cancer stem cells (CSC) are characterised by specific
markers, which very much depend on the origin of the
CSC’ssurroundingtissue.Cancerstemcellsareinitiating
and sustaining carcinomas, because they are self-regen-
erating and remain resting in most carcinomas. Other
cancer cells make up the largest part of malignant cells;
however, they do not contribute to the malignancy of the
illness to the same extent. It is of particular interest, that
some cancer stem cells resist the common chemother-
apiesandradiotherapiesandshowalowimmunogenicity.
Thisresistancecouldexplainwhytumoursvanishinitially
after such therapies mentioned above, but often occur
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again later. A therapy, which specifically targets cancer
stem cells, could improve the chances of recovery. It is
widely believed that the present therapies target the
“normal” tumour cells which form the major part of the
tumour, but it is also believed, that new concepts must
be developed, which reliably eliminate the considerably
more resistant cancer stem cells [41], [42]. For this pur-
pose a large number of existing data originate from
studiesofdifferentcancerousentities,neverthelessthere
is a large number of data already, which were verified on
HNSCC.
2.1 Definition and characteristics of
cancer stem cells
From healthy stem cells we know their function of self-
regeneration and their ability to differentiate into cells of
various tissues. The present findings about cancer stem
cells demonstrate that they extend those abilities pos-
sessed by normal tissue stem cells [43], [44]:
• Unlimited self-regeneration
• Differentiation into various cell types
• Loss of control of proliferation
• Initiation of malignant tumours on a single cell basis
via symmetric proliferation
• Expression of cancer stem cell specific markers
Thus the tumour possesses at least two entities of cells
– the tumour initiating cancer stem cell and those cells
(nontumorigeniccells)originatingfromcancerstemcells,
which have lost their ability of self-regeneration [43].
2.2 Source of cancer stem cells
Thepresenttheoryofformationofheadandneckcancer
canbesummarisedasfollows:Causedbyaquestionably
geneticdispositionduringachronicinflammationcaused
bypermanenttobaccoandalcoholabuse,mechanicirrit-
ation or viral infection, a spontaneous accumulation of
various genetic alterations develops leading to a mani-
festation of a malignant phenotype. Then clonal diver-
gence and selection lead to a formation of a carcinoma.
This accumulation of genetic alterations can appear
synchronouslyormetachronouslyintheareaoftheentire
inflammation of the exposed mucosa which leads to the
so called “field-cancerization” [45], [46].
If one carries over the afore-mentioned to the present
assumption of the genesis of cancer stem cells, certain
parallelisms can be verified, whereby the formation of
cancer stem cells is not conclusively clarified for any tu-
mour entity. Currently three hypotheses are discussed
[47].
1. Source of “normal” stem cells with cancerous pheno-
type.
2. Source from differentiated cells with oncogenic
mutation (Return to self-regeneration and multipo-
tency)
3. Fusion of stem cells with tumour cells (much dis-
cussed with the formation of bone metastases)
Whatevermechanismfortheformationofatumourstem
cell one presumes, the offspring cells will retain the sig-
nalling pathways and characteristics of the source cell
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they originated from, although many of the signalling
pathways are downregulated and therefore inactive.
2.3 Stochastic or hierarchic expansion
of tumours
Currently two models describing growth behaviour are
being discussed and compared. The stochastic model
describestheuptonowpursuedthesis,thattherewould
beone“mothercancelcell”,whichstochasticallyprolifer-
ates by entry into the cell cycle, whereby each cell within
thetumourpossessesthesameabilitytopromotetumour
growth. Therefore each cell is equally potent to initiate a
tumour. The heterogeneity of the tumour is explained by
spontaneous shifts in the phenotype (Figure 2).
In contrast to the above is the hierarchic system, which
splits the cells of a tumour in at least two entities: The
tumour initiating cancer stem cell and its differentiated
offspring with various degrees of maturation, which lost,
however, the ability to initiate a tumour [48], [49]. It is
the subject-matter of current research to what extent the
heterogeneity of tumour cells within a tumour can be
ascribedtothosevariousdegreesofmaturation.Intheory
one CSC would be sufficient to initiate a tumour, which
developsthesamehistologicalphenotypeasthetumour,
from which the CSC originated from (Figure 2).
As far as HNSCC is concerned it has not been finally
clarified which model is valid. One can find arguments
for a rather evolutionary formation of a carcinoma, but
many things can be explained with differentiation.
Therefore there is much to be said for the hierarchic
system. Thus, malignant cells within the vicinity of the
carcinoma have the same biological behaviour, which
can be explained rather with differentiation than with
evolution.Furthermorethemetastasesshowedthesame
heterogeneity than the primary tumour albeit without
being exposed to the same DNA damaging noxa.
The quantity of CSC which is needed to develop a car-
cinoma of identical origin varies among the tumour en-
tities are determined by replantation studies in the
mouse. Currently the quantity fluctuates between 10
3
and 10
7 cells [48], [50]. The reason certainly lies in the
purity of the isolated and defined as CSC cell population,
which can be classed as low for HNSCC due to non exist-
ing markers.
2.4Surfacemarkersforcharacterisation
of cancer stem cells in HNSCC
The definition and isolation of CSC is subject to the
problem, that many markers are necessary, which are
also expressed in ordinary cells. It is the subject-matter
ofcurrentresearchtoidentifyacleardefinitionandaddi-
tionallytoidentifyacleardefinitionofparticularlyinvasive
subgroups where applicable. Currently the hereinafter
characterised markers are used; more are being tested.
2.4.1 CD44
TheisolationandcharacterisationofrecentCSCinHNSCC
revolved around the marker CD44 [50]. CD44 is not suf-
ficient, because as a glycoprotein of the cell surface it
takes part in many cell-cell interactions, cell adhesion
and migration. In humans CD44 is present in a plurality
of splice variants, which already have been linked with
cell transformation and tumour progression before the
discovery of CSC. Thus, the CD44h is the receptor for
hyaluronic acid and therefore it is a relevant connecting
link in the regulation of extracellular matrix interactions.
CD44v6 was linked with the progression of laryngeal
carcinoma but CD44 and CD44v6 are also expressed in
many benign tissues of the aerodigestive tract. The
quantity of the real CSC cannot be determined alone by
the measurement of CD44. Furthermore CD44 is ex-
pressed in all stem cells of hemopoietic origin. A combin-
ation of lineage markers (CD2, CD3, CD10, CD18, CD31,
CD64andCD140),whichmustbenegative,ismandatory
[51],[52],[53].EventhecombinationofCD44+lin-leads
to a selection of cells, which requires a very high number
of cells in the tumour induction of the mouse, thus, it
does not represent an aggressive or well-assorted popu-
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entrenchedHNSCClinesarealsoseverelyCD44+lin-[52].
2.4.2 CD24
CD24 is a cell adhesion molecule, which is expressed on
the surface of many B cells and in differentiating neuro-
blasts.Itencodesasialoglycoprotein,whichisexpressed
in many mature granulocytes and B cells and in CSC as
recently was shown [54].
2.4.3 ALDH1
Only recently Aldehyde Dehydrogenase 1, a member of
the cytosolic enzymes, which catalyses the oxidation of
the aromatic aldehydes in carboxylic acids, was verified
as a potential marker for CSC in HNSCC [55], [56]. In
othercancerentitiesitcouldbedemonstratedthatALDH1
plays a role in the conversion of retinol into retinoic acid,
which is important for proliferation, differentiation and
survival of, for example, keratinocytes. The activity of
ALDH1isresponsiblefortheresistanceofprogenitorcells
towards chemotherapeutic substances, because it can
breakdowncytotoxicdrugs[57].ALDH1positivecellsare
increasingly identified as an objective of therapeutic
measurements [58], [59], [60].
2.4.4 CD133
CD133isaubiquitousmarkerforhemopoieticstemcells,
endothelial progenitor cells, glioblastoma, neuronal and
glial stem cells. It actively takes part in the change of the
plasma membrane [61]. For HNSCC an influence on the
expressioninCD133foranincreasedrateofrecidivation
and secondary neoplasms was verified [62]. An implica-
tion of CD133+ in combination with other markers is not
clearly investigated yet [63], [64], [65], [66].
2.5Surfacemarkersforcharacterisation
of cancer stem cells in HNSCC
Both healthy stem cells and cancer stem cells show a
great variety of signal transduction pathways, which are
necessarytomaintainthestemness(integrityandpotency
of a stem cell) and other various functions of the stem
cells. The following have come into view of current re-
search:Wnt/frizzled,Oct4,Snail,Twist,Sox,Nanog,hCG,
GSC, E-cadherin, AFP, GATA-4, HNF-3 beta/FoxA2, PDX-
1/IPF1, Otx2, TP63/TP73L, Goosecoid (GSC) and many
moreothers.Theimplicationofthosesignallingpathways
shall be exemplarily illustrated by the Wnt signalling
pathway, which is the best researched way with regards
to HNSCC.
2.5.1 Wnt signalling pathway
The Wnt signalling pathway is involved in the regulation
of most different biological processes like, for example,
embryogenesis, cell proliferation and cell migration.
Having different differentiation and transformation pro-
cesses at the back of one’s mind the signalling pathway
also takes part in tumour suppression and oncogenesis.
The cause of an increased cancer risk often lies in a de-
regulation as a result of mutations, e.g. breast cancer or
colon carcinoma [67].
The team around Roel Nusse discover the Wnt1 protein
under the name of Int1. They found out, that mice, in
which that protein has been over-expressed, contract
breast carcinoma. The Wnt1 protein, which holds a pref-
erential integration site of the mouse mammary tumour
virus (MMTV) and therefore has been named proto-onco-
gene Int1, was responsible for it [68]. At the same time
a mutation of the wingless gene (wg) was described for
a wingless variant of the common fruit fly drosophila
melanogaster. By comparison of the sequences both
genes have been associated with each other and finally
were named Wnt [69].
Figure 1 illustrates the canonic Wnt signalling pathway.
With the help of various cofactors the Wnt proteins bind
on the transmembrane receptors of the Frizzled family
andviatheß-catenin,thecentralcomponent,theregula-
tion is carried out. By the receptor complex’s Wnt signal
astabilisationandsubsequentaccumulationofß-catenin
inthenucleusismadepossible,sothatageneexpression
of target genes can take place with the help of transcrip-
tion factors.
Cytoplasmic ß-catenin is subject to a permanent degrad-
ationprocess.Newlysynthesizedß-cateninisimmediately
bound to the tumour suppressor genes “Adenomatous
Polyposis Coli” (APC) and axin. The activity and bonding
of ß-catenin to those two proteins is increased by the
phosphorylation of the glycogen synthase kinase 3
(GSK3). Subsequently ß-catenin is phosphorylated and
degraded into serine/threonine by the kinases [70].
Implication of the Wnt pathway for HNSCC
Even before the identification of CSC in HNSCC by Prince
et al. in 2007 [50], as early as 2002 it was verified on
permanent HNSCC lines which were compared with
healthy epithelial cells, that HNSCC lines show consider-
ablyincreasedlevelsofmRNAforWnt-1,7a,10b,13and
for Fz-2. A blockade of the Wnt pathway by means of an-
tibodies led to a reduction of the factor LEF/TCF which
is required for the transcription of Wnt and reduced the
expressionofcyclind1andtheß-cateninpathway.Italso
ledtoaninhibitionofproliferationandinducedtheapop-
tosis in the HNSCC [71]. Yang et al. [72] could verify that
the Wnt/beta catenin signalling pathway suppresses the
receptor mediating apoptosis in HNSCC.
In so doing not only the tumour necrosis factor (TNF)/c-
Myc-mediated apoptosis, but also the cell detaching
mediated apoptosis (anoikis), which is dependant on the
receptor-mediated pathway, is averted. The Wnt/beta
catenin signalling pathway induced cell detachment in
otherwise adherent growing HNSCC and supported inva-
sive growth in Matrigel [72].
5/12 GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2011, Vol. 10, ISSN 1865-1011
Wollenberg: Implication of stem cells in the biology and therapy ...Other research groups could demonstrate that cells with
over-expressed Wnt signals behave highly invasive in
vitro, tumorigenic in vivo and chemoresistant towards
BortezomibandEtoposide[73].InastudyofsolidHNSCC
an association of high expression of WNT7a and Frizzled
5mRNAwithreducedlengthofsurvivalbecameapparent
[74]. This could be confirmed with other markers along
the Wnt pathway. A new transcription factor Rap1 was
identified, which effectuates the stable and stability and
nuclear translocation of the beta catenin. Clinically this
is associated with more advanced lymph nodes stadia of
the illness [75].
3. Epithelial-mesenchymal
transition (EMT) in head and neck
cancer
The development of a complex organism is based on a
networkofnumerouscontrolmechanismsandastringent
controlled order of events. It initially starts with the epi-
thelial-mesenchymal transition, i.e. the transition of epi-
thelial cells in cells with mesenchymal characteristics. In
1982thisdevelopmentalandbiologicalprocesswasfirst
describedbyGreenburgandHay[76].Cell-to-cellcontacts
are broken up by down-regulation of various adherence
molecules like E-cadherin and specific signalling mo-
lecules (Wnt/ß-catenin, FGF or TGFß1/BMP) induce the
cell migration and the development of mesenchymal
characteristics.
EMT triggers changes in the expression, in the intracellu-
lar distribution and in the function of various growth
factors(TGF-ß,transforminggrowthfactorbeta),transcrip-
tionfactors(Snail,nuclearß-catenin),celltocelladhesion
molecules(cadherins,claudines,occludines),cell-matrix
adhesion molecules (integrins), modulators of the cyto-
skeleton (Rho GTPases) and extracellular proteases
(matrix metalloproteinases) [77].
As the transition advances the cytokeratins, which take
part in the composition of intermediate filaments, are
oftenreplacedwithvimentin.Furthermoremoleculeslike
fibronectin and vitronectin, which enables the cells with
an increasing feature to migrate, are increasingly ex-
pressed. Caused by those changes the epithelial cells
loose their rounded shape and are now able to migrate
through the basement membrane [78], [79], [80].
Those events of the embryonic development are very
similar to those cellular processes regarding the meta-
stasis of malignant tumours. There, too, the tumour cells
obtain the ability to migrate via a phenotype change. In
epithelialtumourssinglecellscandissociatethemselves
fromthecellcolonythiswayandtheycanspreadthrough
the blood system or lymphatic system and form new tu-
mours in other locations.
The necessary dissociation of single epithelial tumour
cells, which is required for metastasis, often has been
linked with EMT processes [80], [81]. The loss of cell
adhesion structures alone, however, does not define an
epithelial-mesenchymal transition and therefore the
problem of identifying reliable EMT bio-markers and the
further characterisation of developing post-EMT cells re-
mains [82], [83].
As early as 2006 gene expression analyses showed a
significant correlation between tumour aggression and
expression profiles of various genes in the areas of EMT
and cell adhesion [84]. Additionally further correlations
between tumour progression and EMT regulation are
known.
As a result of an activation of FGFRIIB- tyrosine kinase
andsuccessiveSrc-,Rasandsignallingcascadesbladder
carcinoma cells differentiate to wandering fibroblasts
[85]. Furthermore a SNAI1 dependant regulation of vari-
ous EMT associated genes was verified for colorectal
carcinoma cells. Snail suppresses the expression of
E-cadherin,whichisacelladhesionprotein,andtherefore
plays an important role in the synthesis of mesenchyme
from epithelial cell colonies [86].
In mouse models it was verified for breast cancer, that
theprogressionandthemetastasisofregressivetumours
was stimulated again by the expression of Snail. The
formattingtumoursconsistedofmesenchymalcells[87].
Furthermore in the aggressive-invasive ductal breast
canceranover-expressionoftheEMTtranscriptionfactor
FOXC2 was verified [88]. Therefore a model has been
described, in which classic activators of EMT like Snail1
or Twist-1, form cells with mesenchymal characteristics
out of epithelial tumour cells, which are called cancer
stem cells (CSC). Those cells are able to perform self-re-
generation and they are able to promote maturation and
multiplication in the remainder of the non CSC tumour
cells. In this way they contribute to tumour initiation, tu-
mour progression, tumour invasion and metastasis
(Ouyang et al., 2010). Because various signalling cas-
cades like Wnt are involved in the ENT in embryology as
wellasintheregulationofstemcells,coherencebetween
EMT, stem cells and tumour formation, tumour growth
and metastasis is assumed.
To date only singular observations are reported in head
and neck cancer giving significance for EMT to single
proteins like TrkB, ZEB1, NBS1 or Stat3 [89], [90], [91],
[92].
4. Stem cell reservoir and tumour
niches
The number of postnatal tissue, in which stem cells or
progenitor cells were found, has increased dramatically
in recent years. Stem cell reservoirs, so called niches,
wereshowninmanytissues.Thosenichesfeaturespecial
conditions and structures, which are necessary for self-
preservation and regulation of stem cells. In an in vitro
culture many of those cells show an enormous plasticity
and they can differentiate into various specialised cell
types. Thereby it is particularly remarkable, that the
numberofstemcelltypes,towhichpluripotentcharacter-
istics are attributed to, also increased recently. Those
6/12 GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2011, Vol. 10, ISSN 1865-1011
Wollenberg: Implication of stem cells in the biology and therapy ...cells are capable of differentiate into cell types of the
three embryonic areas.
There is evidence to suggest that tumour stem cells can
revive cancerous illnesses after an initially successful
therapy and furthermore can be regarded as the source
of metastases. Of great relevance for the preservation of
thosestemcellcharacteristicspresumablyisthesocalled
“stem cell niche”, i.e. the immediate neighbourhood of
the cell, which is defined both by the anatomic structure
and by cellular and non-cellular parameters. The tumour
tissue apparently holds such niche properties and it is
characterised by the expression of certain surface mo-
lecules such as cadherins, catenins or integrins [93],
[94], [95].
The surrounding tissue and the supporting extracellular
matrix are of extraordinary importance for the formation
and preservation of a tumour. They rule its identity and
its cellular behaviour. If, for instance, ordinary somatic
cells are removed from their "niche environment” and
cultivated, often retrodifferentiation processes become
apparent [96].
By implication it became apparent in transplantation ex-
periments with stem cells showing already malignant
degeneration caused by oncogenic mutations, that they
donotinducetumourgrowthinahealthyniche.However,
if healthy stem cells were transplanted in pre-damaged
tissue, tumours emerged from them. There is much to
besaidfor,thatthenicheisplayingaroleinthelaststeps
ofamalignantdegeneration[97].Oneofthemechanisms
through which niche factors influence the destiny of
cancer stem cells is the control and decision over the
proliferation of symmetric (two identical cells) vs. asym-
metric proliferation (one identical and one differentiated
cell). Factors secreted by the tumour stroma influence
the stem cell niche of the tumour microenvironment and
provide a suitable setting for tumour expansion. It is en-
tirely not understood by which stimuli and for what reas-
ons dormant cancer stem cells are being re-activated
after years in their niche and long after a cancer therapy.
5. Therapeutic implications
For HNSCC only a few papers regarding CSC therapy
strategies are available. Taking studies on other cancer
entitiesandthemodelofhierarchictumourinitiationinto
account the following order of events must be adopted
(Figure 3). The heterogenic tumour will be treated with
conventional means. During the surgical intervention re-
sidual cancer cells remain in the incisal margin, in the
neighbourhood of the tumour and in the adjacent tissue
space; those will be treated postoperatively or primarily
with combined or primary radiotherapy. The heterogenic
tumour’s differentiated tumour cells will be destroyed.
Theconsiderablychemo-andradio-resistantcancerstem
cells remain; because of their stem cell characteristics
they are able to generate a tumour, which histologically
matches the tissue from where it originated from (Figure
3).
This model further emphasizes the immense implication
of safe margins during surgical measures and demon-
strates that the objective of future therapies must be the
development of specific drugs against the cancer stem
cells of a tumour, which remain after the removal of the
tumourbulkviaconventionaltherapytreatments.Studies
willberequiredwhichconsidertheconditionofcellslike,
for example, the resting cell cycle phase G0, abilities of
self renewal, the ability to pass cytotoxic substances out
of the cell and many other mechanisms of therapy resist-
ance.
Initial approaches to treat CSC in HNSCC are emerging
from the study of such mechanisms. However, none of
thosestudiescanberegardedasevencloseofaclinical-
translational realisation. Similar to other immunothera-
peutic approaches the biggest problem lies in the select-
ive reachability of cancer stem cells, because they use
the same mechanisms, on which the healthy stem cells
depend on, too, and this makes a specific targeting diffi-
cult.
The chosen therapy approaches to date have only been
tested in vitro or in the mouse model.
Self renewal cascades
Until now the targeting of self renewal cascades have
been tried using different techniques like on the above-
mentionedWnt/Frz-system.Itwasverifiedonpermanent
HNSCClineswhichwerecomparedwithhealthyepithelial
cells, that HNSCC lines show considerably increased
levels of mRNA for Wnt-1, 7a, 10b, 13 and for Fz-2. A
blockade of the Wnt pathway by means of antibodies led
to a reduction of the factor LEF/TCF which is required for
the transcription of Wnt and reduced the expression of
cyclin d1 and the ß-catenin pathway. It also led to an in-
hibition of proliferation and induced the apoptosis in the
HNSCC [71]. Goto et al. could identify RAP1 as a factor,
which increases the nuclear translocation of ß-catenin,
the core element of the Wnt signal. An inhibition of RAP1
via small interfering RNA (siRNA) could reduce the trans-
location,lowertheexpressionofmatrixmetalloproteinase
7, a transcription of catenin, and thereby functionally
lower the invasiveness of HNSCC [75]. A regulation via
inhibition of RAP1 is a possible approach in immunother-
apy, because high levels of ß-catenin are associated with
advanced tumour stages.
Butalsootherselfrenewalcascadeshavecomeintoview
oftherapeuticdeliberations.Thus,Chenetal.havefound
a better response rate of CSC towards radiation by the
use of siRNA transmitted silencing of BMI, which is an
essential protein of a self renewal cascade [59]. In the
same way Snail could be silenced. Snail is believed to be
one of the triggers of EMT, which actively transforms
epithelial cells into migrating mesenchymal cells and in
doingsoactivelysuppressestheexpressionofE-cadherin,
desmoplakin and cytokeratin.
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T cell therapies and the implication of malignant tissue
As early as 2007 it could be verified, that ALDH1 is an
immunogenic epitope, which can be recognised by
CD8+ T cells. With all the limitations a T cell response
implicatesinHNSCCpatients,anantigen-specificimmun-
otherapy towards the epitope of ALDH1 seems possible
[58].
In the future there will presumably be a stark change in
thinking throughout the tumour therapy caused by the
results of research. After all the carcinoma cells them-
selves were in the limelight of most therapy models. In
recent years, however, it proved to be true how important
thetumourstromaisfortheformation,sustainabilityand
also for the tumour eradication. In a mouse model tu-
mours were used, in which the cancer cells expressed a
tumour antigen to a lower extent only. When highly spe-
cific T lymphocytes were then administered in the mouse
against this tumour antigen, a tumour decrease came
along with it, but the tumour recovered quickly, because
the non antigen carrying tumour stroma had not been
attacked and individual cancer cells, which did not ex-
press the antigen anymore, could grow further. If, how-
ever, the tumours have been treated with radiotherapy
or chemotherapy before the T cell transfer, complete tu-
mour eradication occurred. Caused by radiation and
chemotherapyalsoareleaseoftumourantigenoccurred,
whichwasabsorbedbythetumourstromaandexpressed
toitscells.ThenthetransfectedTcellsattackedboththe
antigen carrying cancer cells and the tumour stroma. As
aresultthecancercells,whichlosttheantigen,werealso
killed,becausetheirsubservingtumourstromahadbeen
killed by the T lymphocytes [98]. However, the role of the
tumour vessels for the optimal migration of T cells is very
interesting in this context, too. Caused by G-protein sig-
nalling5(RGS5)areducedmaturationofpericytes,which
areimportantfortheformationofnormalvessels,occurs
in tumour vessels. The tumour vessels therefore show
distinct leakages for plasma proteins and also cause a
worsened oxygenation of tissue. Interestingly those ves-
sels also act as a stark barrier against the migration of
T lymphocytes into the tumour, whereby the underlying
mechanisms are not really understood. However, if the
G-protein signalling 5 was blocked, the pericytes could
mature fully and the tumour vessels became apparently
more stable. This resulted in an improved oxygenation of
the tumour, but it also resulted in an enforced T cell mi-
gration, which, in return, could attack the tumour tissue
[99].
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